This drug has boxed warnings. These are the most serious warnings from the Food and Drug Administration (FDA). A boxed warning alerts doctors and patients about drug effects that may be dangerous.
Ed Silverman, a senior writer and Pharmalot columnist at STAT, has been covering the pharmaceutical industry for nearly three decades. He is also the author of the morning Pharmalittle newsletter and ...
Aug. 22, 2005 — The European Commission has approved adalimumab subcutaneous injection for the treatment of psoriatic arthritis and as first-line therapy for severe, active, and progressive rheumatoid ...
The first biosimilars referencing Humira became available in 2023. That year, 10 FDA-approved adalimumab are now on the ...
A major California health plan has struck a novel deal directly with a drug manufacturer for a cheaper version of Humira, cutting out pharmacy benefit managers — controversial middlemen in the drug ...
SIMLANDI is the first high-concentration, citrate-free biosimilar to Humira that has been granted an interchangeability status by the FDA, and will qualify for interchangeable exclusivity for the 40mg ...
In May 2025, the FDA approved numerous biosimilars as interchangeable with Stelara ® (ustekinumab) and Humira ® (adalimumab), bringing the total number of Stelara ® interchangeables to four, plus an ...
Humira (adalimumab) has potential interactions with several other drugs. For example, taking prednisone with Humira can increase the risk of side effects from both drugs. Humira may also interact with ...
When CVS Caremark removed AbbVie’s Humira from its national commercial formularies back in April, biosimilar prescriptions picked up at a whirlwind pace. Now, Cigna’s Express Scripts is following suit ...
Humira is a type of immunosuppressant known as a tumor necrosis factor (TNF) inhibitor. It’s prescribed to treat autoimmune conditions. TNF is a protein that plays a key role in inflammation. In ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results